^(131)I-chTNT单克隆抗体放射免疫治疗14例晚期胰腺癌  

^(131)I-chTNT Radioimmunotherapy of 14 Patients with Advanced Pancreatic Cancer

作　　者：徐霁充[1] 张家兴[2] 李茂全[2] 吕中伟[2] 曹传武[2] 虞岑琳 张晶[2] 

机构地区：[1]同济大学附属同济医院介入科 [2]同济大学附属第十人民医院介入科

出　　处：《中国医学计算机成像杂志》2016年第5期451-453,共3页Chinese Computed Medical Imaging

摘　　要：目的:通过对14例晚期胰腺癌病人瘤体内注射^(131)I-chTNT(^(131)I标记的肿瘤细胞核单克隆抗体)治疗胰腺癌的疗效和毒性观察,探索一种新的胰腺癌治疗方法。方法:所有胰腺癌患者(n=14)均经细胞学或组织学病理确诊。采用计算机断层扫面引导下瘤体内直接注射^(131)I-chTNT注射液(50m Ci)。结果:14例患者中,完全缓解(CR)1例(7%),部分缓解(PR)4例(29%),稳定(SD)7例(50%),进展(PD)2例(14%),有效率CR+PR 36%。结论:足够剂量的^(131)I—chTNT单克隆抗体瘤体内注射对于晚期胰腺癌的治疗效果显著,安全有效。Purpose： To explore a new therapeutic method for pancreatic cancer by observing the effect and toxicity of ^131I-chTNT （iodine-131-1ablbed tumor necrosis therapy chimeric antibody） in the treatment 14 patients with advanced pancreatic cancer. Method： All pancreatic cancer patients （n=14） were diagnosed by cytology or histology, and were treated with ^131I-chTNT intratumoral injection guided by computed tomography （CT）. Results： One patient had a complete response （CR） （7%）, 4 achieved partial response （PR） （29%）, 7 were stable （50%）, and 4 were progressed （14%）. The response rate was 36%. Conclusions： These promising results demonstrate that sufficient doses of ^131I-chTNT can be safely delivered to tumors to cause significant therapeutic effects in advanced pancreatic cancer.

关 键 词：单克隆抗体 肿瘤学 ^131I标记的肿瘤细胞核单克隆抗体 胰腺癌 放射免疫治疗 

分 类 号：R735.9[医药卫生—肿瘤]